How big is the global healthcare market?
Oncology novel active substance (NAS) launches worldwide (cumulative) stood at 132 in 2020–2024 (IQVIA).
Healthcare statistics
140 verified statistics on the healthcare industry, drawn from 7 primary sources and covering 7 regions. Every figure links to the report it came from.
Primary sources
7
Indicators
97
Regions
7
Period
1983–2050
At a glance
Cell and gene therapy venture capital and public funding deal count
The lead series for this industry. Forecasts are dashed with hollow markers. Download the underlying rows from the data table below.
Cell and gene therapy venture capital and public funding deal count
Global, 2021 to 2023
Source: IQVIA · CC BY 4.0 · statorigin.org
The short version
Key takeaways
Each line is a complete, citable statement. Use the copy button to take the citation with the number.
Connectivity
- Global Initiative for Childhood Cancer country coverage stood at 90 as of 15 September 2026 (WHO). WHO ↗ T1 Official
Other
- Oncology novel active substance (NAS) launches worldwide (cumulative) stood at 132 in 2020–2024 (IQVIA). IQVIA ↗
- Global Platform participating governments stood at 12 as of 15 September 2026 (WHO). WHO ↗ T1 Official
- Global Platform participating countries stood at 12 as of 15 September 2026 (WHO). WHO ↗ T1 Official
- Cell and gene therapy spending worldwide totalled 5.9 billion USD in 2023 (IQVIA). IQVIA ↗
- Medicine spending worldwide totalled 1.6 trillion USD in 2023 (IQVIA). IQVIA ↗
- Market shaping strategy interventions worldwide stood at 10 as of 15 September 2026 (WHO). WHO ↗ T1 Official
- Number of neglected tropical diseases worldwide reached 21 as of 14 September 2026 (WHO). WHO ↗ T1 Official
- Cell and gene therapy venture capital and public funding deal value worldwide stood at 3.4 billion USD in 2023 (IQVIA). IQVIA ↗
- Childhood cancer incidence worldwide stood at 400,000 in 2026 (WHO). WHO ↗ T1 Official
- Oncology medicine spending at list prices worldwide averaged 252 billion USD in 2024 (IQVIA). IQVIA ↗
- COVID-19 pandemic economic losses worldwide stood at 10 trillion USD in 2020–2023 (World Bank). World Bank ↗ T1 Official
- IQVIA projects countries (excluding U.S.) driving global pharmaceutical spending growth at 14 in 2025–2030. IQVIA ↗
- Cell and gene therapy spending growth rate worldwide came in at 38% in 2023 (IQVIA). IQVIA ↗
Answered from the data
Common questions
Which country leads in healthcare?
United States recorded the highest oncology novel active substance (nas) launches (cumulative) at 85 in 2020–2024 (IQVIA).
How fast is the healthcare market growing?
Oncology clinical trial starts growth rate worldwide came in at -4% in 2024–2025 (IQVIA).
What are the key market share figures for healthcare?
Share of human rabies transmissions caused by dogs worldwide stood at 99% as of 14 September 2026 (WHO).
What is the forecast for healthcare?
IQVIA projects novel active substance launches, forecast annual average worldwide at 75 in 2026–2030.
Where does this healthcare data come from?
Every figure on this page traces to a primary source: 7 organisations publish the underlying data, and the dataset spans 1983 to 2050. The full source table lists each report, its publication date and the original link.
How often is this page updated?
The dataset was last verified on 17 September 2026. Annual series are refreshed when the publisher releases a new edition; corrections are accepted at any time and answered within 48 hours.
Visualised
Healthcare charts
Rendered as plain SVG, so they work with JavaScript disabled and can be embedded anywhere. Forecasts are drawn dashed, with hollow markers.
Multi-country oncology trial starts
Global, 2015 to 2024
Source: IQVIA · CC BY 4.0 · statorigin.org
Oncology novel active substance (NAS) launches (annual)
Global, 2015–2019 to 2024
Source: IQVIA · CC BY 4.0 · statorigin.org
The complete table
All healthcare data points
Grouped by indicator. Every row links to its own page with the full source, quote and citation. The CSV includes provenance columns so each downloaded row stays citable.
140 data points across 97 indicators. Each line shows the latest value; open a line for earlier periods and forecasts.
IndicatorRegionPeriodValueSourceType
Aggregate revenue of patient organizationsUnited States2016–202062.5 billion USDIQVIA2020actual→
AMR-driven annual global GDP reductionGlobal20503.8%World BankT12050forecast→
Annual revenue growth rate of largest patient organizationsUnited States2016–20205%IQVIA2020actual→
Average annual revenue of patient organizationsUnited States2016–202012.5 billion USDIQVIA2020estimate→
Cell and gene therapy clinical trial starts +1 more Global2023631IQVIA2023actual→
Cell and gene therapy reimbursement rateEuropean Unionas of 1 Apr 202342%IQVIA2023actual→
Cell and gene therapy share of medicine spendingGlobal20230.4%IQVIA2023actual→
Cell and gene therapy spendingGlobal20235.9 billion USDIQVIA2023actual→
Cell and gene therapy spending average annual growth rateGlobal2019–202365%IQVIA2023actual→
Cell and gene therapy spending growth rateGlobal202338%IQVIA2023actual→
Cell and gene therapy venture capital and public funding deal count +3 more Global2023100IQVIA2023estimate→
Cell and gene therapy venture capital and public funding deal valueGlobal20233.4 billion USDIQVIA2023actual→
Change in regional share of global clinical trial country uses +4 more European Union2019–2025-17%IQVIA2025actual→
- European Union2019–2025-17%IQVIA2025actual→
- European Union2019–202321%IQVIA2023actual→
- North America2019–202317%IQVIA2023actual→
- China2019–202357%IQVIA2023actual→
Childhood cancer incidenceGlobal2026400,000WHOT12026estimate→
Childhood cancer medicines lacking child-friendly formulationsGlobalas of 31 Jan 20246WHOT12024actual→
Commercial insurance out-of-pocket cost growth (5-year)United States2021–202537%IQVIA2025actual→
Countries (excluding U.S.) driving global pharmaceutical spending growthGlobal2025–203014IQVIA2030forecast→
COVID-19 pandemic economic lossesGlobal2020–202310 trillion USDWorld BankT12023estimate→
Domestic-only oncology NAS launches (cumulative)China2020–202445IQVIA2024actual→
Drug overdose deathsUnited States2025–202667,798CDCT12026estimate→
Drug overdose deaths year-over-year changeUnited States2025–2026-12.3%CDCT12026estimate→
Global Initiative for Childhood Cancer beneficiariesGlobalas of 15 Sep 2026500,000WHOT12026estimate→
Global Initiative for Childhood Cancer country coverageGlobalas of 15 Sep 202690WHOT12026actual→
Global Platform participating countriesGlobalas of 15 Sep 202612WHOT12026actual→
Global Platform participating governmentsGlobalas of 15 Sep 202612WHOT12026actual→
Health and social services investment growth rateChinaJanuary 2026-13%NBS ChinaT12026actual→
Health care and medical services price index growth rate +2 more ChinaAugust 20262.7%NBS ChinaT12026actual→
Healthcare expenditureUnited Kingdom2023292 billion GBPONST12023estimate→
Healthcare expenditure as share of GDP +1 more United Kingdom202310.9%ONST12023estimate→
- United Kingdom202211.1%ONST12022estimate→
Healthcare expenditure growth, nominalUnited Kingdom20235.6%ONST12023estimate→
Healthcare expenditure growth, realUnited Kingdom2023-1.4%ONST12023estimate→
Hospitals receiving Medicare IPPS paymentsUnited States2011–20123,000CMST12012actual→
Kindergarten vaccination coverage declineUnited States2025–20260.1%CDCT12026actual→
Lung cancer screening rate among eligible program membersUnited States202454%CDCT12024actual→
Manufacture of medicines producer price index growth rate (monthly) +1 more ChinaAugust 2026-0.2%NBS ChinaT12026actual→
Market shaping strategy interventionsGlobalas of 15 Sep 202610WHOT12026actual→
Medical services price index (monthly) +1 more ChinaAugust 20260.1%NBS ChinaT12026actual→
Medicare IPPS discharge volume (top 100 DRGs)United States2011–20127,000,000CMST12012actual→
Medicare out-of-pocket cost decline rateUnited States20252.2%IQVIA2025actual→
Medicare out-of-pocket cost increase rate versus 2020United States2020–202523%IQVIA2025actual→
Medicine market average annual growth at net prices (5-year)United States2021–20259.3%IQVIA2025actual→
Medicine spendingGlobal20231.6 trillion USDIQVIA2023actual→
Medicine spending growth rate forecast (annual, high estimate)Global2025–20308%IQVIA2030forecast→
Medicine spending growth rate forecast (annual, low estimate)Global2025–20305%IQVIA2030forecast→
Medicine use index (2020=100)China2020100 indexIQVIA2020actual→
Medicine use volumeGlobal20304 trillion defined daily dosesIQVIA2030forecast→
Multi-country oncology trial share +1 more Global202420%IQVIA2024actual→
Multi-country oncology trial starts +2 more Global2024403IQVIA2024actual→
National lung cancer screening rateUnited States202218%CDCT12022actual→
Net medicine spending growth rate +1 more United States202510.6%IQVIA2025actual→
- United States2024–202510.6%IQVIA2025actual→
NHS dental appointment satisfaction rateUnited Kingdomas of 12 Aug 202689.9%ONST12026actual→
Non-retail share of medicine useUnited States202516%IQVIA2025actual→
Novel active substance launches +3 more Global202579IQVIA2025actual→
- Global202579IQVIA2025actual→
- United States202553IQVIA2025actual→
- United States202553IQVIA2025actual→
Novel active substance launches, five-year total +3 more Global2021–2025388IQVIA2025actual→
- Global2021–2025388IQVIA2025actual→
- United States2021–2025270IQVIA2025actual→
- United States2021–2025270IQVIA2025actual→
Novel active substance launches, five-year total (excluding COVID-19 products) +1 more Global2021–2025369IQVIA2025actual→
Novel active substance launches, forecast annual average +1 more Global2026–203075IQVIA2030forecast→
Novel active substance launches, forecast five-year growth +1 more Global2026–2030375IQVIA2030forecast→
Novel active substances launched exclusively in China +1 more China202530IQVIA2025actual→
Novel modality share of oncology trialsGlobal202435%IQVIA2024actual→
Number of neglected tropical diseasesGlobalas of 14 Sep 202621WHOT12026actual→
Oncology clinical trial startsGlobal20242,162IQVIA2024actual→
Oncology clinical trial starts growth rate +1 more Global2024–2025-4%IQVIA2025actual→
Oncology medicine spending at list prices +1 more Global2024252 billion USDIQVIA2024actual→
Oncology medicine spending growth (5-year)Global2019–202475%IQVIA2024actual→
Oncology medicine spending growth (annualized)Global2020–202411.9%IQVIA2024actual→
Oncology novel active substance (NAS) launches (annual) +2 more Global202425IQVIA2024actual→
Oncology novel active substance (NAS) launches (cumulative) +5 more Global2020–2024132IQVIA2024actual→
Patient organization-life sciences company deal valueUnited States2008–20232.4 billion USDIQVIA2023estimate→
Patient organization-life sciences company dealsUnited States2008–2023700IQVIA2023estimate→
People affected by neglected tropical diseasesGlobalas of 14 Sep 20261 billionWHOT12026estimate→
Pharmaceutical manufacturing investment growth rateChinaJanuary 2026-9.8%NBS ChinaT12026actual→
Phase I clinical trial enrollment duration increaseGlobal2019–202339%IQVIA2023actual→
Phase I clinical trial enrollment duration increase (months)Global2019–20235 monthsIQVIA2023actual→
Phase I share of oncology trialsGlobal202438%IQVIA2024actual→
Phase II clinical trial enrollment duration increaseGlobal2019–202323%IQVIA2023actual→
Phase II clinical trial enrollment duration increase (months)Global2019–20236 monthsIQVIA2023actual→
Phase II share of oncology trialsGlobal202448%IQVIA2024actual→
Phase III clinical trial enrollment duration increaseGlobal2019–202316%IQVIA2023actual→
Phase III share of oncology trialsGlobal202414%IQVIA2024actual→
Prescription medicine use growthUnited States20251.5%IQVIA2025actual→
Prescription medicine use growth (5-year)United States2021–202513%IQVIA2025actual→
Private dental appointment satisfaction rateUnited Kingdomas of 12 Aug 202693.5%ONST12026actual→
Rare cancer share of oncology trial startsGlobal202474%IQVIA2024actual→
Reduction in human dog-mediated rabies casesLatin America and the Caribbean1983–202698%WHOT12026actual→
Retail pharmacy prescription drug average annual growth (5-year)United States2021–20252.4%IQVIA2025actual→
Retail share of medicine useUnited States202584%IQVIA2025actual→
Rural Health Transformation Program state investment +4 more United Statesas of 15 Sep 2026104 million USDCMST12026actual→
- United Statesas of 14 Sep 20261.25 million USDCMST12026actual→
- United Statesas of 10 Sep 202611.7 million USDCMST12026actual→
- United Statesas of 9 Sep 20264.8 million USDCMST12026actual→
- United Statesas of 4 Sep 202676 million USDCMST12026actual→
Share of global pharmaceutical spending growth from top 15 countriesGlobal2025–203076%IQVIA2030forecast→
Share of human rabies transmissions caused by dogsGlobalas of 14 Sep 202699%WHOT12026estimate→
Traditional Chinese medicines price index (monthly) +1 more ChinaAugust 20260%NBS ChinaT12026actual→
Unfilled prescription rate (all brands and branded generics)United Statesend of 202529%IQVIA2025actual→
Value added growth rate of pharmaceutical manufacturing +1 more ChinaJuly 20262.8%NBS ChinaT12026actual→
Western medicines price index (monthly) +1 more ChinaAugust 2026-0.1%NBS ChinaT12026actual→
WHO operational locationsGlobalas of 14 Sep 2026150WHOT12026actual→
WHO presence locationsGlobalas of 15 Sep 2026150WHOT12026actual→
Primary documents
Sources
The complete list of documents behind this page. Nothing is hidden and nothing is behind a disclosure.
| Document | Publisher | Authority tier | Published | Accessed | Locator | Data points |
|---|---|---|---|---|---|---|
| CDC Launches New Overdose Prevention Data Channel Press release | CDC | T1 Official | — | 16 Sep 2026 | RELEASE | 2 |
| CDC Statement on Newly Released Kindergarten Vaccination Data Press release | CDC | T1 Official | — | 16 Sep 2026 | STATEMENT | 1 |
| Twenty-Five Years After 9/11 Press release | CDC | T1 Official | — | 16 Sep 2026 | WTC Health Program lung cancer screening findings | 2 |
| Data Press release | CMS | T1 Official | — | 16 Sep 2026 | Medicare provider utilization & payment data: Inpatient Hospital Public Use File (PUF) | 2 |
| Newsroom Articles Press release | CMS | T1 Official | — | 16 Sep 2026 | Trump Administration Announces $104 Million to Transform Rural Healthcare Across Mississippi Through Cutting-Edge Technology and Expanded Care Closer to Home; Trump Administration Expands Preventive and Behavioral Healthcare Access for Students Across Rural North Carolina; Trump Administration Announces $11.7 Million to Expand Access, Improve Patient Care Facilities, and Strengthen Workforce Capacity in Nursing Homes and Long-Term Care System Across Rural Vermont | 5 |
| Investment in Fixed Assets from January to July 2026 Press release | NBS China | T1 Official | — | 15 Sep 2026 | Table: Investment in Fixed Assets (Excluding Rural Households) from January to July 2026 | 2 |
| Consumer Price Index in August 2026 Press release | NBS China | T1 Official | — | 16 Sep 2026 | I. Year-on-Year Changes in Price Indexes for Various Goods and Services; Consumer Price Indexes in August 2026 | 8 |
| National Economy Remained Steady with Innovation-Led and High-Quality Development in August Press release | NBS China | T1 Official | — | 15 Sep 2026 | 7. Consumer Price Rose Mildly and Producer Prices for Industrial Products Grew Faster Year on Year. | 1 |
| Industrial Producer Price Indexes in August 2026 Press release | NBS China | T1 Official | — | 15 Sep 2026 | Table: Industrial Producer Price Indexes in August 2026 — III. Producer Price Indexes for Major Industries (Growth Rate M/M column); Table: Industrial Producer Price Indexes in August 2026 — III. Producer Price Indexes for Major Industries (Jan-Aug Growth Rate Y/Y column) | 2 |
| Industrial Production Operation in July 2026 Press release | NBS China | T1 Official | — | 15 Sep 2026 | Value Added of the Main Industries | 2 |
| Health care system Press release | ONS | T1 Official | — | 16 Sep 2026 | Spotlight: Healthcare expenditure, UK Health Accounts: 2022 and 2023; Experiences of NHS healthcare services in England: September 2026 | 7 |
| Health Emergencies Press release | World Bank | T1 Official | — | 16 Sep 2026 | Context | 2 |
| New strategy to build a healthier market for childhood cancer medicines Press release | WHO | T1 Official | — | 16 Sep 2026 | New strategy to build a healthier market for childhood cancer medicines; Note to the editor; Implementing the foundations of the strategy | 7 |
| WHO advances access to quality-assured, child-friendly cancer medicines Press release | WHO | T1 Official | — | 16 Sep 2026 | From identifying needs to stimulating product development | 1 |
| Chile becomes first country in South America validated for eliminating dog-transmitted rabies as a public health problem Press release | WHO | T1 Official | — | 16 Sep 2026 | About rabies and neglected tropical diseases; A regional success with global lessons; About WHO | 5 |
| Supporting patients through research collaboration Press release | IQVIA | T3 Research | — | 16 Sep 2026 | Over the past 5 years patient organizations have received over 62.5 billion in revenue; Key findings | 5 |
| Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Cell and gene therapy clinical trial starts by type, 2013-2023; Status of cell and gene therapy reimbursement in Europe (Apr 2023) compared to GDP per capital 2022, current international dollars PPP; Key findings | 13 |
| Global R&D Trends 2026 Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Exhibit 55: Country utilization as percentage of global trial country uses, 2019 and 2025; Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025; Key Findings | 10 |
| Global R&D Trends 2026 Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Exhibit 55: Country utilization as percentage of global trial country uses, 2019 and 2025; Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025; Key Findings | 10 |
| Rethinking Clinical Trial Country Prioritization Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Key findings; Enrollment is taking longer across all phases of development | 8 |
| U.S. Medicine Use Trends 2026 Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Other Findings; Key Findings | 14 |
| Global Medicine Use Trends 2026 Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Exhibit 19: Global spending and growth, excluding COVID-19 vaccines and therapeutics,constant $USBn, 2020–2030; Exhibit 15: Global medicine market size and growth including estimated COVID-19 vaccine and therapeutic spending, 2016–2030; Key Findings | 6 |
| Global Oncology Trends 2025 Press release | IQVIA | T3 Research | — | 16 Sep 2026 | Other Findings; Key Findings: Oncology R&D activity continues to grow driven by novel modalities; Key Findings: Spending on oncology medicines is growing across geographies and tumors | 25 |
Report snapshots are retained internally for verification only and are never redistributed. Where a figure comes from a paywalled report, only the number published in its public summary is recorded.
All 140 collected records are published as verified.
Cite & reuse
Cite this page
Data on this page is published under CC BY 4.0. You may reuse it, including commercially, provided you attribute it.
StatOrigin. (2026). Healthcare Industry Statistics. Retrieved from https://statorigin.org/industries/healthcare
Found an error? Every figure here is checkable against its
source, and we would rather be corrected than be wrong. Report a problem; we
respond within 48 hours, and corrections are logged publicly on the corrections page.
This page was last generated on 18 September 2026 from a verified dataset snapshot. It is rebuilt whenever the underlying data changes.